UA120765C2 - Терапевтичне лікування на основі анамореліну - Google Patents

Терапевтичне лікування на основі анамореліну Download PDF

Info

Publication number
UA120765C2
UA120765C2 UAA201702308A UAA201702308A UA120765C2 UA 120765 C2 UA120765 C2 UA 120765C2 UA A201702308 A UAA201702308 A UA A201702308A UA A201702308 A UAA201702308 A UA A201702308A UA 120765 C2 UA120765 C2 UA 120765C2
Authority
UA
Ukraine
Prior art keywords
week
anamorelin
patient
anam
patients
Prior art date
Application number
UAA201702308A
Other languages
English (en)
Ukrainian (uk)
Inventor
Вільям Манн
Вильям Манн
Джон ФРЕНД
Вільям Польвіно
Вильям Польвино
Сюзан Аллен
Мін Лю
Мин ЛЮ
Елізабет Дуус
Элизабет ДУУС
Рубен Джорджіно
Рубэн Джорджино
Енріко Бароні
Энрико БАРОНИ
Original Assignee
Хелсінн Хелскеа Са
Хелсинн Хелскеа Са
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55436476&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UA120765(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Хелсінн Хелскеа Са, Хелсинн Хелскеа Са filed Critical Хелсінн Хелскеа Са
Publication of UA120765C2 publication Critical patent/UA120765C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
UAA201702308A 2014-09-04 2015-08-28 Терапевтичне лікування на основі анамореліну UA120765C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462045976P 2014-09-04 2014-09-04
PCT/US2015/047435 WO2016036598A1 (en) 2014-09-04 2015-08-28 Medical treatments based on anamorelin

Publications (1)

Publication Number Publication Date
UA120765C2 true UA120765C2 (uk) 2020-02-10

Family

ID=55436476

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201702308A UA120765C2 (uk) 2014-09-04 2015-08-28 Терапевтичне лікування на основі анамореліну

Country Status (44)

Country Link
US (5) US9675600B2 (enExample)
EP (2) EP3590338A3 (enExample)
JP (3) JP6356907B2 (enExample)
KR (3) KR102234319B1 (enExample)
CN (5) CN107375285A (enExample)
AP (1) AP2017009772A0 (enExample)
AR (1) AR103118A1 (enExample)
AU (1) AU2015312231B2 (enExample)
BR (1) BR112017003552A2 (enExample)
CA (1) CA2959158A1 (enExample)
CL (1) CL2017000494A1 (enExample)
CO (1) CO2017003263A2 (enExample)
CR (1) CR20170121A (enExample)
CY (1) CY1122746T1 (enExample)
DK (1) DK3188599T3 (enExample)
DO (1) DOP2017000055A (enExample)
EA (1) EA035578B1 (enExample)
EC (1) ECSP17019893A (enExample)
ES (1) ES2761777T3 (enExample)
GE (2) GEP20186939B (enExample)
HR (1) HRP20192345T1 (enExample)
HU (1) HUE046894T2 (enExample)
IL (1) IL250692B (enExample)
JO (1) JO3541B1 (enExample)
LT (1) LT3188599T (enExample)
MA (1) MA40607B1 (enExample)
MD (1) MD4710C1 (enExample)
ME (1) ME03597B (enExample)
MX (1) MX361741B (enExample)
MY (1) MY187167A (enExample)
NI (1) NI201700024A (enExample)
PE (1) PE20171109A1 (enExample)
PH (1) PH12017500392B1 (enExample)
PL (1) PL3188599T3 (enExample)
PT (1) PT3188599T (enExample)
RS (1) RS59751B1 (enExample)
SG (1) SG11201701567UA (enExample)
SI (1) SI3188599T1 (enExample)
SV (1) SV2017005400A (enExample)
TN (1) TN2017000040A1 (enExample)
TW (1) TWI639429B (enExample)
UA (1) UA120765C2 (enExample)
UY (1) UY36286A (enExample)
WO (1) WO2016036598A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014159609A1 (en) 2013-03-14 2014-10-02 Allergen Research Corporation Peanut formulations and uses thereof
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료
US12433945B2 (en) 2018-08-16 2025-10-07 Société des Produits Nestlé S.A. Peanut oral immunotherapy with maintenance dose
CA3123605A1 (en) 2018-12-20 2020-06-25 Aimmune Therapeutics, Inc. Peanut oral immunotherapy dosing schedule for missed doses
CA3137295A1 (en) 2019-05-10 2020-11-19 Aimmune Therapeutics, Inc. Methods for improving the quality of life of a patient with a peanut allergy
JP7854809B2 (ja) 2019-08-30 2026-05-07 ヘルシン ヘルスケア ソシエテ アノニム 安定性が改善されたアナモレリン錠剤の製造方法
AU2020372131B2 (en) * 2019-10-24 2025-10-30 Toray Industries, Inc. Therapeutic or prophylactic agent for cachexia
JP2024534464A (ja) * 2021-09-17 2024-09-20 小野薬品工業株式会社 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
JPWO2025004650A1 (enExample) * 2023-06-28 2025-01-02

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303620B1 (en) 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
ECSP993020A (es) 1999-06-16 1999-08-12 Terapia de combinacion para la fragilidad musculoesqueletica
ECSP993021A (es) 1999-06-16 1999-08-12 Combinaciones terapeuticas para la fragilidad musculoesqueletica
US20010020012A1 (en) 2000-02-01 2001-09-06 Andersen Maibritt Bansholm Use of compounds for the regulation of food intake
CN1863550A (zh) * 2003-08-06 2006-11-15 加斯特罗泰克药物公司 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用
JP2007523048A (ja) * 2003-08-06 2007-08-16 ガストロテック・ファルマ・アクティーゼルスカブ 分泌促進物質の使用
US20050261201A1 (en) 2004-03-30 2005-11-24 Rejuvenon Corporation Method of reducing C-reactive protein using growth hormone secretagogues
EP2298760B1 (en) * 2004-06-29 2015-08-05 Helsinn Healthcare S.A. Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide
KR20090112720A (ko) * 2007-02-13 2009-10-28 헬신 세라퓨틱스 (유.에스.) 인크. 성장 호르몬 분비촉진제를 이용한 세포 증식 질환의 치료방법
TWI429436B (zh) 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
JO3353B1 (ar) 2012-04-20 2019-03-13 Ono Pharmaceutical Co شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي
EP2854810A4 (en) * 2012-05-25 2016-04-06 Raqualia Pharma Inc GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA
KR102234319B1 (ko) 2014-09-04 2021-04-01 헬신 헬쓰케어 에스.에이. 아나모렐린 기반의 의학적 치료

Also Published As

Publication number Publication date
CA2959158A1 (en) 2016-03-10
CN113577074A (zh) 2021-11-02
SG11201701567UA (en) 2017-03-30
KR20210035923A (ko) 2021-04-01
AR103118A1 (es) 2017-04-19
ES2761777T3 (es) 2020-05-21
NZ729673A (en) 2023-09-29
CO2017003263A2 (es) 2017-07-28
SV2017005400A (es) 2017-04-20
EP3188599A1 (en) 2017-07-12
JO3541B1 (ar) 2020-07-05
WO2016036598A1 (en) 2016-03-10
KR20180085047A (ko) 2018-07-25
LT3188599T (lt) 2019-12-10
US20170296526A1 (en) 2017-10-19
JP2018154655A (ja) 2018-10-04
PT3188599T (pt) 2020-01-15
AP2017009772A0 (en) 2017-02-28
EP3590338A2 (en) 2020-01-08
US10278964B2 (en) 2019-05-07
PL3188599T3 (pl) 2020-06-01
CN113577073A (zh) 2021-11-02
RS59751B1 (sr) 2020-02-28
DOP2017000055A (es) 2017-08-15
TWI639429B (zh) 2018-11-01
KR102307275B1 (ko) 2021-09-30
CN107205389A (zh) 2017-09-26
JP2017526695A (ja) 2017-09-14
US9675600B2 (en) 2017-06-13
EP3590338A3 (en) 2020-03-18
MX361741B (es) 2018-12-14
JP6356907B2 (ja) 2018-07-11
PH12017500392A1 (en) 2017-07-17
TN2017000040A1 (en) 2018-07-04
EP3188599B1 (en) 2019-10-02
MD4710B1 (ro) 2020-09-30
JP7044918B2 (ja) 2022-03-30
US10894041B2 (en) 2021-01-19
CL2017000494A1 (es) 2017-09-15
US20160067236A1 (en) 2016-03-10
MA40607B1 (fr) 2019-11-29
US20190175574A1 (en) 2019-06-13
UY36286A (es) 2016-02-29
US20240024303A1 (en) 2024-01-25
GEAP201814459A (en) 2018-09-10
IL250692B (en) 2019-05-30
EA035578B1 (ru) 2020-07-09
GEP20186939B (en) 2018-12-25
EP3188599A4 (en) 2017-10-11
MD4710C1 (ro) 2021-04-30
US11723902B2 (en) 2023-08-15
AU2015312231B2 (en) 2017-10-19
CN107375285A (zh) 2017-11-24
CR20170121A (es) 2017-07-17
US20210093627A1 (en) 2021-04-01
PH12017500392B1 (en) 2018-08-31
KR101881264B1 (ko) 2018-07-23
KR20170047372A (ko) 2017-05-04
ME03597B (me) 2020-07-20
JP2021080281A (ja) 2021-05-27
CY1122746T1 (el) 2021-03-12
NI201700024A (es) 2017-07-18
IL250692A0 (en) 2017-04-30
HUE046894T2 (hu) 2020-04-28
MD20170025A2 (ro) 2017-07-31
AU2015312231A1 (en) 2017-03-23
BR112017003552A2 (pt) 2017-12-05
ECSP17019893A (es) 2017-05-31
HRP20192345T1 (hr) 2020-03-20
MY187167A (en) 2021-09-07
KR102234319B1 (ko) 2021-04-01
CN109172575A (zh) 2019-01-11
TW201613587A (en) 2016-04-16
PE20171109A1 (es) 2017-08-07
JP6923486B2 (ja) 2021-08-18
DK3188599T3 (da) 2019-11-25
EA201790352A1 (ru) 2017-07-31
MX2017002825A (es) 2017-09-28
SI3188599T1 (sl) 2020-02-28

Similar Documents

Publication Publication Date Title
JP7044918B2 (ja) アナモレリンに基づく医療
Muñoz et al. The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists
Choy et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non–small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study)
USRE45105E1 (en) Method of treating cancer by co-administration of anticancer agents
US11666549B2 (en) Regulation of cancer using natural compounds and/or diet
JP7132848B2 (ja) 癌の治療のための合理的併用療法
HK40020876A (en) Medical treatments based on anamorelin
HK1234959A1 (en) Medical treatments based on anamorelin
HK1234959B (en) Medical treatments based on anamorelin
JP2024534464A (ja) 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法
OA18229A (en) Medical treatments based on anamorelin.
NZ729673B2 (en) Medical treatments based on anamorelin